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esponsibility of Xi’Abstract A simple, sensitive and speciﬁc liquid chromatography–tandem mass spectrometry (LC–MS/MS)
method was developed for the quantiﬁcation of milnacipran (MC) in rat plasma by using the liquid–liquid
extraction method. Milnacipran-d10 (MCD10) was used as an internal standard (IS). Chromatographic separation
was achieved on Zorbax SB-CN (4.6 mm 75 mm, 3.5 mm) column with an isocratic mobile phase composed
of 10 mM ammonium acetate (pH 4.0) and methanol in the ratio of 25:75(v/v), at a ﬂow-rate of 0.7 mL/min. MC
and MCD10 were detected with proton adducts at m/z 247.2-230.3 and m/z 257.2-240.4 in multiple reaction
monitoring (MRM) positive mode respectively. The method was validated over a linear concentration range of
1.00–400.00 ng/mL with a correlation coefﬁcient (r2)≥0.9850. This method demonstrated intra- and inter-day
precision within 5.40–10.85% and 4.40–8.29% and accuracy within 97.00–104.20% and 101.64–106.23%. MC
was found to be stable throughout three freeze–thaw cycles, bench top and postoperative stability studies. This
method was successfully applied to a pharmacokinetic study of rats through i.v. administration.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Elsev
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an Jiaotong University.1. Introduction
Milnacipran (1-phenyl-1-diethylamino-carbonyl-2-amino-methyl-
cyclopropane hydrochloride) is a new antidepressant which is
characterized by serotonin and noradrenalin reuptake inhibitor
(SNRI) and by virtual absence of postsynaptic effects. Chemically,ier B.V. All rights reserved.
K. Kanala et al.482it is (1R, 2S)-rel-2-(aminomethyl)-N, N-diethyl-1-phenylcycl-
opropane carboxamide hydrochloride. It has an empirical formula
of C15H22N2O HCl and a molecular weight of 282.8 g/mol
(Fig. 1). The indications for these medicines include treatment of
depression, Generalised Anxiety Disorder (GAD), Social Anxiety
Disorder (SAD), panic disorder and diabetic peripheral neuropathy
(duloxetine only). The exact mechanism of the central pain inhibitory
action of MC and its ability to improve the symptoms of ﬁbromyalgia
in humans are unknown. Preclinical studies have shown that MC is a
potent inhibitor of neuronal norepinephrine and serotonin reuptake;
MC inhibits norepinephrine uptake with approximately 3-fold higher
potency in vitro than serotonin without directly affecting the uptake of
dopamine or other neurotransmitters. MC is well absorbed after oral
dosing and has a bioavailability of 85%. Meals do not have an
inﬂuence on the rapidity and extent of absorption. Peak plasma
concentrations are reached 2 h after oral dosing. The Cmax of 50 mg
oral dose is about 126.18727.90 ng/mL. The elimination half-life of
8 h is not increased by liver impairment and old age, but by signiﬁcant
renal disease. MC is conjugated to the inactive glucuronide and
excreted into the urine as unchanged drug and conjugate. Only traces
of active metabolites are found. Enzymes of the CYP class do not play
a role in the metabolism of MC so that the risk of interactions with
drugs metabolized by CYP enzymes is minimal [1–4].
Literature survey reveals that, there are few methods reported
for quantiﬁcation of MC in pharmaceutical [5–8] and biological
ﬂuids [9–11]. These are quantiﬁed by several techniques including
capillary electrophoresis [5], micellar electro kinetic capillary [6],
liquid chromatography (LC) [7–10] and LC–MS/MS [11]. How-
ever, LC–MS/MS has played an important role for the quantitative
estimation of drugs in various biological matrices, including
plasma, serum, urine, and ocular ﬂuids, due to its high sensitivity,
selectivity and reproducibility. Most of the published methods in
the literature are liquid–liquid [9,10] and solid-phase extraction
(SPE) [11] of MC in human plasma. Among all Shinozuka et al.
[11] developed the most sensitive method in human plasma by
using LC–MS/MS. However, it is required to develop the simplest,
sensitive method with proper internal standard usage[12–14].
The aim of the proposed method is to develop the simplest,
sensitive, high recovery and selective extraction method (liquid–
liquid extraction). As per standard regulatory guidelines, it could
be successfully employed in the analysis of rat plasma samples
following i.v. administration in healthy rats.2. Materials and methods
2.1. Chemicals and reagents
MC was obtained from MSN Pharmachem Pvt. Ltd. (MR0021011)
(99.80% purity), Hyderabad, India and MCD10 was obtained from
Clearsynth (AC0202158) (100.00% purity). Ammonium acetateFig. 1 Chemical structures of milnacipran and milnacipran-d10.and acetic acid were purchased from Merck, Mumbai, India.
Methanol and acetonitrile were purchased from J.T BAKER, USA.
Rats and rat plasma were obtained from Bioneeds, Bangalore.
2.2. LC–MS/MS instrument and conditions
The 1200 Series HPLC system (Agilent Technologies, Germany) was
used. Mass spectrometric detection was performed on an API 4200
triple quadrupole instrument (ABI-SCIEX, Toronto, Canada) using
MRM. Data processing was performed on Analyst 1.5.1 software
package (SCIEX). Detection was performed by Turbo ionspray (API)
positive mode with Unit Resolution. For MC, the MH+ (m/z 247.2)
was monitored as the precursor ion and a fragment at m/z 230.3 was
chosen as the product ion. For internal standard, the MH+ (m/z 257.2)
was monitored as the precursor ion and a fragment at m/z 240.4 was
monitored as the product ion. Mass parameters were optimized as
source temperature 550 1C, heater gas 40 (nitrogen) psi, nebulizer gas
50 (nitrogen) psi, curtain gas 30 (nitrogen) psi, CAD gas 2 (nitrogen)
psi, ion spray (IS) voltage 5500 V, source ﬂow rate 600 mL/min
without split, entrance potential 10 V, declustering potential 45 V for
analyte and 45 V for IS, collision energy 20 V for analyte and 20 V
for IS, collision cell exit potential 10 V for both analyte and IS.
2.3. Chromatographic conditions
ZORBAX SB-CN column (4.6 mm 75 mm, 3.5 mm) was selected
as the analytical column. The mobile phase composition was
10 mM ammonium acetate (pH 4.0) and methanol in the ratio of
25:75 (v/v). The ﬂow rate of the mobile phase was set at 0.7 mL/
min. The column temperature was set at 40 1C. MCD10 was found
to be an appropriate internal standard in terms of chromatography
and extractability. The retention time of MC and MCD10 was found
to be 1.770.2 min approximately at overall 3 min run time.
2.4. Preparation of standards and quality control (QC) samples
Standard stock solutions of MC (100.00 mg/mL), and the IS
(100.00 mg/mL) master stock solutions were prepared in methanol.
The IS spiking solutions (400.00 ng/mL) were prepared in 50%
methanol from IS master stock. Master stock solutions and IS spiking
solutions were stored in refrigerator at 2–8 1C until analysis. Master
stock solutions were added to drug-free rat plasma to obtain MC
concentration levels of 1.00, 2.00, 5.00, 20.00, 40.00, 80.00, 160.00,
240.00, 320.00 and 400.00 ng/mL for analytical standards and 1.00,
3.00, 200.00 and 300.00 ng/mL for quality control standards. These
standards were stored in the freezer at −30 1C until analysis. The
aqueous standards were prepared in reconstitution solution [75%
methanol in 10 mM ammonium acetate (pH 4.0)] for validation
exercises and stored in the fridge at 2–8 1C until analysis.
2.5. Sample preparation
The liquid–liquid extraction method was used to isolate MC, and
its respective IS from rat plasma. For this, 50 mL of IS (400.00 ng/
mL) and 100 mL of plasma sample (respective concentration) were
added into labeled polypropylene tubes and vortexed brieﬂy after
that 2.5 mL of methyl t-butyl ether was added and vortexed for
approximately 10 min followed by centrifuged at 4000 rpm for
approximately 5 min at 20 1C. Supernatant from each sample was
transferred to labeled ria vial tube and evaporated at 40 1C until
dryness. These samples were reconstituted with 500 mL of
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acetate (pH 4.0)] and vortexed brieﬂy, and then transferred the
sample into autosampler vials for injection.
2.6. Method validation
2.6.1. Selectivity and speciﬁcity
The selectivity of the method was determined by six different rat
blank plasma samples, which were pretreated and analyzed to test
the potential interferences of endogenous compounds co-eluting
with analyte and IS. Chromatographic peaks of analyte and IS
were identiﬁed based on their retention times and MRM responses.
The peak area of MC at the respective retention time in blank
samples should not be more than 20% of the mean peak area of
LOQ of MC. Similarly, the peak area of MCD10 at the respective
retention time in blank samples should not be more than 5% of the
mean peak area of LOQ of MCD10.
2.6.2. Matrix effect
To predict the variability of matrix effect in samples from
individual subjects, matrix effect was quantiﬁed by determining
the matrix factor, which was calculated as follows:
Matrix factor¼
Peak response ratio in the presence of extracted matrix
Peak response ratio in neat standards ðaqueousstandardsÞ
Six lots of blank biological matrices were spiked each in
triplicates with the neat standard at the low quality control (LQC),
high quality control (HQC) levels, and compared with neat
standards of the same concentration in alternate injections. The
overall precision of the matrix factor is expressed as coefﬁcient of
variation (CV %) and it should be ≤15% (CV %).
2.6.3. Linearity
The analytical curves were constructed using concentratons ranging
from 1.00 to 400.00 ng/mL of MC in rat plasma. Calibration curves
were obtained by weighted 1/conc.2 linear regression. The ratio of MC
peak area to MCD10 peak area was plotted against the ratio of MC
concentration in ng/mL. Calibration curve standard samples and
quality control samples were prepared in replicates (n¼6) for analysis.
The correlation coefﬁcient was obtained 40.9850 by using a simple
linear regression model in the whole range of tested concentrations.
2.6.4. Precision and accuracy
Precision and accuracy for the back calculated concentrations of the
calibration points, should be within ≤15% and 715% of their
nominal values. However, for lower limit of quantiﬁcation (LLOQ)
the precision and accuracy should be within ≤20% and 720%.
2.6.5. Stability
LQC and HQC samples (n¼6) were retrieved from the deep freezer
after three freeze–thaw cycles according to the clinical protocols.
Samples were frozen at −30 1C in three cycles of 24, 36 and 48 h.
In addition, the long-term stability of MC in quality control samples
was also evaluated by analysis after 55 days of storage at −30 1C.
Autosampler stability was studied following 71.5 h storage period in
the autosampler tray with control concentrations. Bench top stability
was studied for 24.5 h period with control concentrations. Stability
samples were processed and extracted along with the freshly spiked
calibration curve standards. The precision and accuracy for thestability samples must be within ≤15% and 715% respectively of
their nominal concentrations.
2.6.6. Recovery
The extraction recovery of analyte and IS from rat plasma was
determined by analyzing quality control samples. Recovery at
three concentrations (3.00, 200.00, and 300.00 ng/mL) was
determined by comparing peak areas obtained from the plasma
sample with those from the standard solution spiked with the blank
plasma residue. A recovery of more than 50% was considered
adequate to obtain required sensitivity.
2.6.7. Limit of quantiﬁcation (LOQ) and limit of detection
(LOD)
The response (peak area) was determined in blank plasma samples
(six replicates from different plasma), and spiked LOQ sample
prepared from the same plasma was determined. The peak area of
blank samples should not be more than 20% of the mean peak area
of LOQ of MC and 5% of the mean peak area of MCD10. The
precision and mean accuracy of the back calculated LOQ replicate
concentrations must be ≤20% and 720%, respectively.
The LOD is a parameter that provides the lowest concentration
in a sample that can be detected from background noise but not
quantitated. LOD was determined using the signal-to-noise ratio
(S/N) of 3:1 by comparing test results from samples with known
concentrations of analyte with those from the blank samples.
2.7. Application to pharmacokinetic study of MC in rat plasma
The validated method has been successfully used to quantify MC
concentrations in rat plasma. The study was conducted according to
current GCP guidelines and approved by an authorized animal ethics
committee. Male Sprague-Dawley rats were obtained from Bioneeds,
Bangalore. After i.v. administration of drug (0.9mg/200g body weight
of rats) through left femoral vein, 0.2 mL of blood samples were
collected via the right femoral vein at speciﬁc time intervals for 39 h.
There was a total of 14 blood collection time points including the
predose sample (0.3, 0.6, 1, 1.5, 2, 4, 7, 11, 15, 21, 27, 33, 39 h). The
blood samples were collected in separate vacutainers containing
K2EDTA as an anticoagulant. The plasma from these samples was
separated by centrifugation at 3000 rpm within the temperature range
of 2–8 1C. The plasma samples thus obtained were stored at –30 1C
until analysis. After analysis the pharmacokinetic parameters were
computed using WinNonlins software version 5.2.3. Results and discussion
3.1. Method development
LC–MS/MS has been used as one of the most powerful analytical
tools in clinical pharmacokinetics for its selectivity, sensitivity and
reproducibility. The goal of this work was to develop and validate
a simple, rapid and sensitive assay method for the quantitative
determination of MC from plasma samples. A simple extraction
technique was utilized for the extraction of MC and MCD10 from
the plasma samples. Chromatographic conditions, especially the
composition and nature of the mobile phase, were optimized
through several trials to achieve better resolution and increase the
signal of MC and MCD10. The MS optimization was performed
by direct infusion of solutions of both MC and MCD10 into the
Fig. 2 Mass spectra of (A) milnacipran parent ion, (B) milnacipran product ion, (C) milnacipran-d10 parent ion and (D) milnacipran-d10
product ion.
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Fig. 3 Chromatogram of blank rat plasma.
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nebulizer and the desolvation gases, were optimized to obtain a
better spray shape, resulting in better ionization and droplet drying
to form. In our case, the protonated ionic MC and MCD10 (IS)
molecules. A product ion spectrum for MC and MCD10 yielded
high-abundance fragment ions of m/z 247.2/230.3 (Fig. 2A and B)
and m/z 257.2/240.4 (Fig. 2C and D). After the MRM channels
were tuned, the mobile phase was changed from an organic phase
to a more aqueous phase to obtain a fast and selective LC method.
A good separation and elution were achieved using 10 mM
ammonium acetate (pH 4.0): methanol 25:75(v/v) as the mobile
phase, at a ﬂow rate of 0.7 mL/min and injection volume of 10 mL.3.2. Method validation
The developed method was validated over a linear concentration
range of 1.00–400.0 ng/mL. The validation parameters, includingselectivity and speciﬁcity, matrix effect, linearity, precision and
accuracy, stability (freeze–thaw, auto sampler, bench top, long
term), recovery, LOQ and LOD, were evaluated under validation
section as per standard guidelines [15,16].
3.2.1. Selectivity and speciﬁcity
The analysis of MC and MCD10 using MRM function was highly
selective with no interfering compounds (Fig. 3). Speciﬁcity was
performed by using six different lots of rat plasma. Here only one
blank plasma interference is shown (Fig. 3). Chromatograms
obtained from plasma spiked with MC (1.00 ng/mL) and
MCD10 (200.00 ng/mL) are shown in Fig. 4.
3.2.2. Matrix effect
The overall precision of the matrix factor was determined to be
6.68 at the low concentration and 4.36 at the high concentration
for MC.
Fig. 4 LLOQ chromatograms of milnacipran and milnacipran-d10.
Table 1 Calibration curves details of MC from one batch of
validation.
Spiked plasma
concentration
(ng/mL)
Mean
concentration
(ng/mL)7SD
RSDa (%)
(n¼5)
Accuracy
(%)
1.00 1.0170.03 2.48 101.40
2.00 1.9970.09 4.57 99.60
5.00 4.6870.24 5.11 93.52
20.00 19.7270.65 3.31 98.59
40.00 40.5971.11 2.73 101.49
80.00 79.7372.85 3.58 99.66
160.00 167.6472.67 1.59 104.77
240.00 245.64710.01 4.07 102.35
320.00 318.50718.34 5.76 99.53
400.00 395.79725.36 6.41 98.95
a(Standard deviation/mean concentration measured) 100.
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Calibration curves were plotted as the peak area ratio (MC/
MCD10) versus (MC) concentration. Calibration was found to
be linear over the concentration range of 1.00–400.00 ng/mL. The
RSDs was less than 5% and the accuracy ranged from 93.52% to
104.77%. The determination coefﬁcients (r2) were greater than
0.9850 for all curves (Table 1).
3.2.4. Precision and accuracy
Precision and accuracy for this method was controlled by
calculating the intra- and inter-batch variations at four concentra-
tions (1.00, 3.00, 200.00 and 300.00 ng/mL) of QC samples in six
replicates. As shown in Table 2, the intra-day RSD was less than
10.85% and the accuracy ranged from 97.00% to 104.20%. Inter-
day RSD was less than 8.29% and the accuracy ranged from
101.64% to 106.23%. These results indicate the adequate relia-
bility and reproducibility of this method within the analytical
curve range.
Table 2 Precision and accuracy of MC from one batch of validation.
Spiked plasma
conc. (ng/mL)
Intra-day Inter-day
Concentration measured (n¼6)
(ng/mL) (mean7SD)
RSDa (%) Accuracy (%) Concentration measured
(n¼30) (ng/mL) (mean7SD)
RSDa (%) Accuracy (%)
1.00 1.0370.11 10.85 103.17 1.0670.09 8.29 106.23
3.00 2.9170.20 6.72 97.00 3.0670.19 6.20 102.01
200.00 208.40711.25 5.40 104.20 203.4878.95 4.40 101.74
300.00 311.65719.23 6.17 103.88 304.93713.77 4.52 101.64
a(Standard deviation/mean concentration measured) 100.
Table 3 Stability of MC in plasma samples.
Stability Spiked plasma
concentration (ng/mL)
Concentration measured (ng/mL)
(mean7SD; n¼6)
RSDa (%) (n¼6)
Room temperature stability (24.5 h) 3.00 2.8570.26 9.14
300.00 298.07713.36 4.48
Processed sample stability (71.5 h) 3.00 3.0870.09 2.84
300.00 310.4678.09 2.60
Long term stability (55 days) 3.00 3.0370.09 2.95
300.00 295.4173.38 1.15
Freeze–thaw stability (cycle 3, 48 h) 3.00 2.8670.20 7.10
300.00 297.1177.46 2.51
a(Standard deviation/mean concentration measured) 100.
Table 4 Mean pharmacokinetic parameters of milnacipran in
rat plasma after intravenous administration of 0.9 mg/200 g
male rat.
Pharmacokinetic parameter Milnacipran values
AUC0–t (ng h/mL) 1345
Cmax (ng/mL) 115
AUC0−∞ (ng h/mL) 1365
Kel (h_1) 0.10303
Tmax (h) 0.3
T1/2 (h) 6.7
AUC0–∞: area under the curve extrapolated to inﬁnity.
AUC0–t: area under the curve up to the last sampling time.
Cmax: the maximum plasma concentration.
Tmax: the time to reach peak concentration.
Kel: the apparent elimination rate constant.
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Quantiﬁcation of MC in plasma subjected to three freeze–thaw
(−30 1C to room temperature) cycles showed the stability of the
analyte. No signiﬁcant degradation of MC was observed even after
71.5 h storage period in the autosampler tray, and the ﬁnal
concentrations of MC was between 102.67% and 103.49% of
the theoretical values. In addition, the long-term stability of MC in
QC samples after 55 days of storage at −30 1C was also evaluated.
The concentrations ranged from 98.47% to 101.11% of the
theoretical values. These results conﬁrmed the stability of MC in
rat plasma for at least 55 days at −30 1C (Table 3).3.2.6. Recovery
The recovery following the sample preparation using the liquid–
liquid extraction method with methyl-t-butyl ether was calculated
by comparing the peak area ratios of MC in plasma samples with
the peak area ratios of solvent samples and estimated at control
levels of MC. The recovery of MC was determined at three
different concentrations 3.00, 200.00 and 300.00 ng/mL and found
to be 103.45%, 104.00% and 112.48%, respectively. The overall
average recovery of MC and MCD10 was found to be 106.64%
and 102.62% respectively.
3.2.7. LOQ andLOD
The LOQ for this method was proven as the lowest concentration
of the calibration curve which was proven as 1.00 ng/mL.
The LOD was determined using aqueous solutions. For MC
10 μL of a 5.0 pg/mL solution was injected to give an on-column
mass of 0.05 pg.
3.3. Pharmacokinetics and statistical analysis
The validated method has been successfully applied to quantify MC
concentrations in rat plasma. The pharmacokinetic parameters
evaluated were Cmax (maximum observed drug concentration during
the study), AUC0-39(area under the plasma concentration–time curve
measured 39 h, using the trapezoidal rule), Tmax (time to observe
maximum drug concentration), Kel (apparent ﬁrst order terminal rate
constant calculated from a semi-log plot of the plasma concentration
versus time curve, using the method of least square regression) and
T1/2 (terminal half-life as determined by quotient 0.693/Kel)[16,17].
Pharmacokinetic details are shown in Table 4. The mean concentra-
tion versus time proﬁle of MC in rat plasma is shown in Fig. 5.
Fig. 5 Mean plasma concentrations versus time graph of milnacipran
after intravenous administration of 0.9 mg/200 g in male rats.
K. Kanala et al.4884. Conclusions
The developed method is rapid, sensitive, rugged and reproducible
with high recovery. Each sample requires less than 3 min of
analysis time. Drug and IS were extracted with the simplest liquid–
liquid extraction method with less matrix effect. The developed
method was successfully applied in the pharmacokinetic study to
evaluate plasma concentration of MC in healthy rats.
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